Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.
about
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human useDesign and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)Carfilzomib-associated tumor lysis syndrome.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibThe novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaDynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-XThe 26S proteasome complex: an attractive target for cancer therapyNew approaches for dissecting protease functions to improve probe development and drug discoveryThe novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphomaTumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/ lymphoma cellsEpithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.Proteasome inhibitors in multiple myeloma: 10 years later.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Carfilzomib in multiple myeloma.Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
P2860
Q28084478-E9128E0D-F3C8-4AB0-877E-16161E5E355FQ31094748-AA3E3328-8AFE-453C-B4E5-892EBF2192E9Q33412480-59EE468E-91FE-4879-B0E6-668A7BC1D5D1Q34317307-655FCE63-B355-4A95-AC77-C8BAA3DCBCB3Q34500544-BFDC21A3-EAEB-4F7B-85FB-2CEF3549BCF3Q35494324-559BBCFC-9881-41AE-BFA9-CF940AFE8D74Q35624079-771FACB7-9E49-4AE9-823C-A7F4A31F9C8BQ36442058-8356C76B-F0F9-4BC0-B2F0-534C12018F10Q37140809-1A8BD865-FE50-4DF8-B1F7-88964A26E14BQ37415621-EA9A25B4-9911-4C89-A77E-A8E413CAC023Q38000940-74090A9F-67D9-406B-98FB-EEE12902E4A1Q38014395-0DACBEE7-F185-497D-AC08-C1DC214FA311Q38035044-1D1F996E-3FFE-4D85-9DB7-F76E4097DFA7Q38244558-27929BF1-5B66-4681-8686-CDDD0FD140C0Q41531584-0599FC65-E4E3-44D2-9D6E-9152429067ADQ41645533-DC711119-9E37-48E4-A27E-5071662E7B81
P2860
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Emerging role of carfilzomib i ...... eoplasms and multiple myeloma.
@ast
Emerging role of carfilzomib i ...... eoplasms and multiple myeloma.
@en
type
label
Emerging role of carfilzomib i ...... eoplasms and multiple myeloma.
@ast
Emerging role of carfilzomib i ...... eoplasms and multiple myeloma.
@en
prefLabel
Emerging role of carfilzomib i ...... eoplasms and multiple myeloma.
@ast
Emerging role of carfilzomib i ...... eoplasms and multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Emerging role of carfilzomib i ...... neoplasms and multiple myeloma
@en
P2093
Jasmine Zain
Owen A O'Connor
Salvia Jain
P2860
P356
10.2147/CE.S13838
P407
P577
2011-04-04T00:00:00Z